FDA OKs Drug for Managing Opioid Withdrawal Symptoms

The FDA approved Lucemyra (lofexidine HCl) to help ease withdrawal symptoms when adults who are addicted abruptly stop taking opioids. "Today's approval represents the first FDA-approved non-opioid treatment for the management of opioid withdrawal symptoms and provides a new option that allows providers to work with patients to select the treatment best suited to an individual's needs," stated Dr. Sharon Hertz, director of the FDA's division of anesthesia, analgesia and addiction products.

Read More